An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization (Q41721418)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 September 2014

Language	Label	Description	Also known as
English	An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization	scientific article published on 28 September 2014

Statements

scholarly article

1 reference

Europe PubMed Central

8 October 2017

An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization (English)

1 reference

Europe PubMed Central

8 October 2017

0 references

0 references

passive immunization

1 reference

based on heuristic

inferred from title

0 references

author name string

Rama Raghunandan

1

1 reference

Europe PubMed Central

8 October 2017

Hanxin Lu

2

1 reference

Europe PubMed Central

8 October 2017

Bin Zhou

3

1 reference

Europe PubMed Central

8 October 2017

Mimi Guebre Xabier

4

1 reference

Europe PubMed Central

8 October 2017

Michael J Massare

5

1 reference

Europe PubMed Central

8 October 2017

David C Flyer

6

1 reference

Europe PubMed Central

8 October 2017

Louis F Fries

7

1 reference

Europe PubMed Central

8 October 2017

Gale E Smith

8

1 reference

Europe PubMed Central

8 October 2017

Gregory M Glenn

9

1 reference

Europe PubMed Central

8 October 2017

language of work or name

0 references

publication date

28 September 2014

1 reference

Europe PubMed Central

8 October 2017

1 reference

Europe PubMed Central

8 October 2017

32

1 reference

Europe PubMed Central

8 October 2017

6485-6492

1 reference

Europe PubMed Central

8 October 2017

48

1 reference

Europe PubMed Central

8 October 2017

Immunity to and frequency of reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Respiratory syncytial virus infection in elderly and high-risk adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

The burden of respiratory syncytial virus infection in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Epidemiology of viral respiratory tract infections in a prospective cohort of infants and toddlers attending daycare.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Respiratory syncytial virus genetic and antigenic diversity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Motavizumab for the prevention of respiratory syncytial virus infection in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Current concepts and progress in RSV vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

New insights for development of a safe and protective RSV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.030

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of primary infection and reinfection with respiratory syncytial virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25269094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

1 reference

https://pubmed.ncbi.nlm.nih.gov/25269094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antigenic structure of human respiratory syncytial virus fusion glycoprotein.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25269094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25269094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Respiratory syncytial virus--the unrecognised cause of health and economic burden among young children in Australia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25269094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/25269094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VACCINE.2014.09.030

1 reference

Europe PubMed Central

8 October 2017

1 reference

Europe PubMed Central

8 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41721418&oldid=2075944557"